IP Library › Granted Patent US 12,186,394
Granted Patent B2
US 12,186,394 · App. 17/946,905 · Granted Jan 7, 2025

Compositions and methods for treatment of pre-cancerous skin lesions

Inventors: Lynn Cornelius (St. Louis, MO); Shadmehr Demehri (St. Louis, MO); Raphael Kopan (St. Louis, MO)
Assignee: Washington University
A61K45/06A61K31/513A61K31/59A61K31/593C07D243/04A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,186,394
App. No.
17/946,905
Granted
Jan 7, 2025
Kind
B2
Abstract

The present disclosure encompasses compositions and methods for the treatment of precancerous skin lesions. Compositions of the invention comprise a cytotoxic agent and a thymic stromal lymphopoietin (TSLP) inducer.

Claims (19)

1. A topical composition comprising about 2% to about 5% (wt/wt) 5-fluorouracil (5-FU) and about 0.002% to about 0.005% (wt/wt) calcipotriol.

2. The composition of claim 1 , wherein the composition comprises from 3% to 5% (wt/wt) 5-fluorouracil (5-FU) and 0.003% to 0.005% (wt/wt) calcipotriol.

3. The composition of claim 1 , wherein the composition further comprises at least one pharmaceutically acceptable excipient.

4. The composition of claim 3 , wherein the composition is formulated as an ointment, cream, suspension, lotion, powder, solution, paste, gel, spray, aerosol, or oil.

5. The composition of claim 4 , wherein the composition is formulated for transdermal or transmucosal administration.

6. The composition of claim 1 , wherein the composition comprises one or more additional drugs or therapeutically active agents.

7. A method of treating a noncancerous skin lesion in a subject in need thereof, the method comprising, topically administering to the noncancerous skin lesion a composition comprising a cytotoxic agent and a thymic stromal lymphopoietin (TSLP) inducer.

8. The method of claim 7 , wherein the TSLP inducer is calcipotriol.

9. The method of claim 7 , wherein the cytotoxic agent is 5-fluorouracil (5-FU).

10. The method of claim 9 , wherein the composition comprises about 2% to about 5% 5-FU.

11. The method of claim 10 , wherein the composition comprises about 0.002% to about 0.005% calcipotriol.

12. The method of claim 7 , wherein the noncancerous skin lesion is a wart or a similar virus infection of the skin.

13. The method of claim 12 , wherein the wart is a plantar wart, cutaneous wart, ano-genital wart, verruca vulgaris, flat wart, filiform wart, or wart-like lesion associated with a virus infection of the skin.

14. A method of treating non-melanoma skin cancer in a subject in need thereof, the method comprising, topically administering to the non-melanoma skin cancer a composition comprising a cytotoxic agent and a thymic stromal lymphopoietin (TSLP) inducer.

15. The method of claim 14 , wherein the TSLP inducer is calcipotriol.

16. The method of claim 14 , wherein the cytotoxic agent is 5-fluorouracil (5-FU).

17. The method of claim 16 , wherein the composition comprises about 2% to about 5% 5-FU.

18. The method of claim 17 , wherein the composition comprises about 0.002% to about 0.005% calcipotriol.

19. The method of claim 14 , wherein the non-melanoma skin cancer is a basal cell carcinoma, Bowen disease, kera-toacanthomas, Merkel cell carcinoma, cutaneous (skin) lymphomas, Kaposi sarcoma, skin adnexal tumors, sebaceous gland carcinoma, or sarcoma.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2023
From: CORNELIUS, LYNN ANNE; DEMEHRI, SHADMEHR; KOPAN, RAPHAEL
To: WASHINGTON UNIVERSITY
Reel/Frame 062309/0125 →
Continuity (4)
Continuation 17140782 · Jan 4, 2021
Continuation 15510443
Provisional Application 62048586 · Sep 10, 2014
Related Publication 20230026855A1 · Jan 26, 2023
References Cited (85)
US 4241046A · Papahadjopoulos et al. · 1980 [cited by applicant]
US 4394448A · Szoka, Jr. et al. · 1983 [cited by applicant]
US 4529561A · Hunt et al. · 1985 [cited by applicant]
US 4755388A · Heath et al. · 1988 [cited by applicant]
US 4820711A · Pearlman · 1989 [cited by applicant]
US 4828837A · Uster et al. · 1989 [cited by applicant]
US 4925661A · Huang · 1990 [cited by applicant]
US 4954345A · Muller · 1990 [cited by applicant]
US 4957735A · Huang · 1990 [cited by applicant]
US 5043164A · Huang et al. · 1991 [cited by applicant]
US 5064655A · Uster et al. · 1991 [cited by applicant]
US 5077211A · Yarosh · 1991 [cited by applicant]
US 5264618A · Felgner et al. · 1993 [cited by applicant]
US 6242435B1 · Achkar · 2001 [cited by applicant]
US 6566495B1 · Fodor et al. · 2003 [cited by applicant]
US 7939313B2 · Heyduk et al. · 2011 [cited by applicant]
US 8299109B2 · Nordsiek et al. · 2012 [cited by applicant]
US 10905763B2 · Cornelius et al. · 2021 [cited by applicant]
US 20050079235A1 · Stockfleth · 2005 [cited by applicant]
US 20050214328A1 · Zeldis · 2005 [cited by applicant]
US 20090098065A1 · Harel · 2009 [cited by applicant]
US 20170246299A1 · Cornelius et al. · 2017 [cited by applicant]
EP 1491188A1 · 2004 [cited by applicant]
WO 0000159A2 · 2000 [cited by applicant]
WO 2006120682A2 · 2006 [cited by applicant]
WO 2010080345A1 · 2010 [cited by applicant]
WO 2012074842A2 · 2012 [cited by applicant]
WO 2012076212A2 · 2012 [cited by applicant]
WO 2012176212A1 · 2012 [cited by applicant]
WO 2016040638A2 · 2016 [cited by applicant]
Clinicaltrials.gov, “History of Changes for Study: NCT02019355 Actinic Keratosis Study (AK),” Clinical Trials Study NCT02019355, Dec. 17, 2013. [cited by applicant]
Examination Report for New Zealand Patent Application No. 730890, dated Sep. 7, 2023, 4 pages. [cited by applicant]
Abel E.L., et al., “Multi-Stage Chemical Carcinogenesis in Mouse Skin: Fundamentals and Applications,” Nature Protocols, 2009, vol. 4, No. 9 pp. 1350-1362. [cited by applicant]
Berth-Jones J., et al., “Vitamin D Analogues and Psoriasis,” British Journal of Dermatology, Blackwell Publishing Ltd, Aug. 1992, vol. 127, No. 2, pp. 71-78. [cited by applicant]
Bucknall M., et al., “Practical Quantitative Biomedical Applications of MALDI-TOF Mass Spectrometry,” Journal of the American Society for Mass Spectrometry, Elsevier Science Inc, 2002, vol. 13, pp. 1015-1027. [cited by applicant]
Communication Pursuant to Article 94(3) EPC in European Patent Application No. 15840602.5, mailed Aug. 17, 2020, 4 Pages. [cited by applicant]
Cornelius L., “Actinic Keratosis Study (AK),” U.S. National Library of Medicine, NCT02019355, ClinicalTrials.gov, Dec. 24, 2013, 7 Pages, Retrieved from URL: https://clinicaltrials.gov/ct2/show/NCT02019355. [cited by applicant]
Davis S.A., et al., “Top Dermatologic Conditions in Patients of Color: An Analysis of Nationally Representative Data,” Journal of Drugs Dermatology, Apr. 2012, vol. 11, No. 4, pp. 466-473. [cited by applicant]
Demehri S., et al., “Elevated Epidermal Thymic Stromal Lymphopoietin Levels Establish an Antitumor Environment in the Skin,” Cancer Cell, Oct. 16, 2012, vol. 22, No. 4, pp. 494-505, DOI: 10.1016/j.ccr.2012.08.017, XP028… [cited by applicant]
Devaux S., et al., “Topical Vitamin D Analogues Alone or in Association with Topical Steroids for Psoriasis: A Systematic Review,” Journal of the European Academy of Dermatology and Venereology, May 2012, vol. 26, Suppl… [cited by applicant]
Di Piazza M., et al., “Loss of Cutaneous TSLP-Dependent Immune Responses Skews the Balance of Inflammation from Tumor Protective to Tumor Promoting,” Cancer Cell, Oct. 16, 2012, vol. 22, No. 4, pp. 479-493, DOI:10.1016/… [cited by applicant]
“Dovonex Cream 0.005% Drug Description,” RxList, The Internet Drug Index, Sep. 23, 2005, pp. 1-2, [Retrieved on Nov. 9, 2015] Retrived from URL: http://www.rxlist.com/dovonex-ointment-drug.htm. [cited by applicant]
Extended European Search Report for European Application No. 15840602.5, mailed Apr. 17, 2018, 9 Pages. [cited by applicant]
Extended European Search Report for European Application No. 21193984.8, mailed Dec. 22, 2021, 11 Pages. [cited by applicant]
Fenske N.A., et al., “Actinic Keratoses: Past, Present and Future,” Journalof Drugs in Dermatology, May 2010, vol. 9. No. 5 (Supplement) ODAC Conf. Pt. 1, pp. s45-s49. [cited by applicant]
Final Office Action for U.S. Appl. No. 15/510,443, mailed Dec. 2, 2019, 15 Pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 15/510,443, mailed Jun. 15, 2018, 12 Pages. [cited by applicant]
Fullerton A., et al., “Guidelines for Measurement of Skin Colour And Erythema. A Report From the Standardization Group of the European Society of Contact Dermatitis,” Contact Dermatitis, 1996, vol. 35, No. 1, pp. 1-10, … [cited by applicant]
Giacomel J., et al., “Pink Lesions,” Dermatologic Clinics, Elsevier Inc, Oct. 2013, vol. 31, No. 4, pp. 649-678. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2015/049434, mailed Mar. 23, 2017, 7 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2015/049434, mailed Dec. 11, 2015, 8 Pages. [cited by applicant]
Kim R.H., et al., “Nonmelanoma Skin Cancer,” Dermatologic Clinics, Elsevier Inc, Jan. 2012, vol. 30, No. 1, pp. 125-139. [cited by applicant]
Ebwohl M., et al., “Ingenol Mebutate Gel for Actinic Keratosis,” New England Journal of Medicine, Mar. 15, 2012, vol. 366, No. 11, pp. 1010-1019, DOI:10.1056/NEJMoa1111170, XP002693228. [cited by applicant]
Li M., et al., “Topical Vitamin D3 and Low-Calcemic Analogs Induce Thymic Stromal Lymphopoietin in Mouse Keratinocytes and Trigger an Atopic Dermatitis,” Proceedings of the National Academy of Sciences of the United Sta… [cited by applicant]
Ma Y., et al., “Vitamin D in Combination Cancer Treatment,” Journal of Cancer, 2010, vol. 1, pp. 101-107. [cited by applicant]
Majewski S., et al., “Combination of Isotretinoin And Calcitriol for Precancerous And Cancerous Skin Lesions,” Lancet, Nov. 26, 1994, vol. 344, No. 8935, pp. 1510-1511. [cited by applicant]
Milczarek M., et al., “Vitamin D Analogs Enhance the Anticancer Activity of 5-fluorouracil in an In Vivo Mouse Colon Cancer Model,” BMC Cancer, Jun. 18, 2013, vol. 13, No. 294, 19 pages. [cited by applicant]
Non Final Office Action for U.S. Appl. No. 15/510,443, mailed May 2, 2019, 15 Pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/510,443, mailed Oct. 6, 2019, 10 Pages. [cited by applicant]
Notice of Allowance for European Patent Application No. 15840602.5, mailed Mar. 26, 2021, 7 Pages. [cited by applicant]
Notice of Allowance for Ukrainian Application No. 201703381, mailed Dec. 16, 2019, 9 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/510,443, mailed Sep. 30, 2020, 08 Pages. [cited by applicant]
Office Action for Australian Patent Application No. 2015315047, mailed Dec. 2, 2019, 04 Pages. [cited by applicant]
Office Action for Australian Patent Application No. 2020281015, mailed Oct. 7, 2021, 5 Pages. [cited by applicant]
Office Action for Brazilian Application No. BR122021004073-7, mailed on Aug. 26, 2022, 3 pages. [cited by applicant]
Office Action for Brazilian Application No. BR122021004073-7, mailed on Dec. 21, 2022, 3 pages. [cited by applicant]
Office Action for Brazilian Patent Application No. BR112017004893-0, mailed Dec. 8, 2022, 05 Pages. [cited by applicant]
Office Action for Canadian Patent Application No. 2,963,922, mailed Nov. 16, 2021, 7 Pages. [cited by applicant]
Office Action for Chinese Patent Application No. 201580060643.8, mailed Mar. 8, 2019, 12 Pages. [cited by applicant]
Office Action for Eurasian Patent Application No. 201790565 mailed Dec. 16, 2019, 6 pages, with English Translation. [cited by applicant]
Office Action for European Patent Application No. 15840602.5, mailed Aug. 13, 2019, 5 Pages. [cited by applicant]
Office Action for Mexican Application No. MX/A/2017/003262, mailed Apr. 9, 2021, 7 Pages. [cited by applicant]
Office Action for Ukrainian Patent Application No. 201703381, mailed Mar. 26, 2019, 11 Pages. [cited by applicant]
Pommergaard H-C., et al., “Topical Combination Of Diclofenac, Calcipotriol, And Difluoromethylornithine Has Beneficial Effects Comparable to 5-fluorouracil For the Treatment of Non-melanoma Skin Cancer in Mice,” Journal… [cited by applicant]
Psorcutan Cream 0.005%, Universal Drugstore, 2 Pages, [Retrieved on Sep. 22, 2017] Retrieved from URL: https://www.universaldrugstore.com/medications/Dovonex+Cream/0.005%25. [cited by applicant]
Rockett J.C., et al., “DNA Arrays: Technology, Options and Toxicological Applications,” Xenobiotica, 2000, vol. 30, No. 2, pp. 155-177. [cited by applicant]
Sato-Deguchi E., et al., “Topical Vitamin D3 Analogues Induce Thymic Stromal Lymphopoietin and Cathelicidin in Psoriatic Skin Lesions,” British Journal of Dermatology, Jul. 2012, vol. 167, No. 1, pp. 77-84. [cited by applicant]
Seckin D., et al., “Can Topical Calcipotriol be a Treatment Alternative in Actinic Keratoses? A Preliminary Report,” Journal of Drugs in Dermatology, May 2009, vol. 8, No. 5, pp. 451-454, XP055417714. [cited by applicant]
Smit J.V., et al., “Actinic Keratoses in Renal Transplant Recipients Do Not Improve with Calcipotriol Cream and All-Trans Retinoic Acid Cream As Monotherapies or in Combination During A 6-week Treatment Period,” British… [cited by applicant]
Soumelis V., et al., “Human Epithelial Cells Trigger Dendritic Cell-Mediated Allergic Inflammation by Producing TSLP,” Nature Immunology, Jul. 2002, vol. 3, No. 7, pp. 673-680. [cited by applicant]
Takahashi H., et al., “Photodynamic Therapy Using a Novel Photosensitizer, TONS501, is Similarly Effective to ALA and EC036 Photodynamic Therapy on DMBA-and TPA-Induced Mouse Skin Papilloma,” Journal of Dermatological S… [cited by applicant]
Tanghetti E.A., “The Role of Topical Vitamin D Modulators in Psoriasis Therapy,” Journal of Drugs Dermatology, Aug. 2009, vol. 8, No. 8 (Supplement), pp. s4-s8. [cited by applicant]
Van Den Bemd G.J.C.M., et al., “Vitamin D and Vitamin D Analogs in Cancer Treatment,” Current Drug Targets, Feb. 1, 2002, vol. 3, No. 1, pp. 85-94. [cited by applicant]
Warino L., et al., “Frequency and Cost of Actinic Keratosis Treatment,” Dermatologic Surgery, Blackwell Publishing Inc., Aug. 2006, vol. 32, No. 8, pp. 1045-1049. [cited by applicant]
Ziegler S.F., et al., “Sensing the Outside World: TSLP Regulates Barrier Immunity,” Nature Immunology, Apr. 2010, vol. 11, No. 4, pp. 289-293, DOI: 10.1038/ni. 1852, XP055453580. [cited by applicant]